Program Schedule

446
Factors Associated with Hospital Length of Stay among Cancer Patients with Febrile Neutropenia

Session: Poster Abstract Session: Transplant Infectious Diseases
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • IDWEEK_LOS_2014.pdf (4.5 MB)
  • Background: Hospital length of stay (LOS) is an important marker of clinical severity and resource consumption in the context of febrile neutropenia (FN). Understanding the factors that increase LOS may increase our knowledge regarding reducing costs and improving the quality of care in FN.  Therefore, we conducted this study with the aim of evaluating the factors associated with increased LOS in hospitalized adult cancer patients with FN. 

    Methods: A prospective cohort study was performed at a single tertiary referral hospital in southern Brazil from October 2009 to August 2011. All adult cancer patients with febrile neutropenia admitted consecutively to the hematology ward were evaluated. A stepwise negative binomial regression was conducted to identify risk factors for prolonged hospital length of stay.

    Results: In total, 307 cases of febrile neutropenia (in 169 patients) were evaluated. The overall median hospital length of stay was 16 days (interquartile range 18 days). After multiple negative binomial regression analysis was performed, hematologic neoplasm (P=0.003), high-dose chemotherapy regimens (P<0.001), duration of neutropenia (P<0.001), and bloodstream infection involving Gram-negative multi-drug resistant bacteria (P=0.003) were independently and directly associated with prolonged hospital length of stay in patients with febrile neutropenia.

    Conclusion: Hematologic neoplasms, high-dose chemotherapy regimens, prolonged periods of neutropenia, and bloodstream infection by Gram-negative multi-drug resistant bacteria increase risk for prolonged hospital length of stay among adult cancer patients with febrile neutropenia.

    Regis Rosa, M.D. M.S., PPG Em Ciências Médicas, Ufrgs - Faculty of Medicine, Porto Alegre, Brazil and Luciano Goldani, PhD, MD, Infectious Diseases Unit, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

    Disclosures:

    R. Rosa, None

    L. Goldani, None

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek